CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- 144 Insider Sale of Securities
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Planned sale Global Head of R&D sold 5,000 shares at an average $257.23 ($1,286,174)
- 4 Planned sale SVP, General Counsel sold 1,202 shares at an average $258.04 ($310,170)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale President, COO & GM China sold 51,921 shares at an average $240.46 ($12,485,045)
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 41,760 shares at an average $225.69 ($9,424,955)
- UPLOAD Other SEC-generated Letter
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-4/A Deal Registration Statement - Business Combination
- 8-K Event Regulation FD disclosure
- 4 Planned sale Director sold 41,760 shares at an average $176.50 ($7,370,515)
- 10-K/A Report 10-K/A
- 144 Insider Sale of Securities
- 8-K Event Other events
- 4 Option exercise Chief Executive Officer acquired 1,300,000 shares (option exercise)
- 4 Planned sale Director sold 41,760 shares at an average $186.90 ($7,805,106)
Page 16 of 64 · 1,278 filings